MUMBAI & BALTIMORE — Lupin Pharmaceuticals last week announced the launch of ciprofloxacin oral suspension in 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500 mg/5 mL) dosage strengths.
The drug is the generic version of Cipro oral suspension from Bayer HealthCare Pharmaceuticals. It's used for the treatment of infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations, according to Lupin.
Lupin was first to file an abbreviated new drug application for Cipro and is entitled to 180 days of market exclusivity. Sales for Cipro oral suspension in the United States totalled $8.6 million as of March 2014, according to IMS data.